For Healthcare Professionals: Clinical Updates in Soft Tissue Sarcoma

Over the past two decades, Memorial Sloan-Kettering's multidisciplinary team of experts has surgically treated more than 8,000 individuals with soft tissue sarcomas – one of the rarest of cancers – and has provided consultations to almost twice that number.

The Soft Tissue Sarcoma Disease Management Team includes specialists in surgery, medical oncology, radiation oncology, diagnostic radiology, nursing, pathology, biostatistics, immunology, epidemiology, and psychiatry.

In pioneering advances in limb-sparing operations that combine radiation therapy and/or chemotherapy, we offer a high rate of tumor control without the need for amputation in many cases. Our physicians and researchers in the laboratory are simultaneously investigating new types of adjuvant treatments for this cancer, including novel chemotherapy agents designed to inhibit tumorigenesis by targeting the tumor cell cycle.

Therapeutic Approach Demonstrates Improved Progression-Free Survival in Patients with Bone and Soft Tissue Sarcoma

Medical oncologist Gary Schwartz explains promising results of a phase II trial examining a novel combination of agents in patients with soft tissue and bone sarcomas.

Runtime: 03:00 minutes Published: 04/02/2013 - 2:50 PM
Phase III Clinical Trial of Doxorubicin Alone or in Combination with TH-302 for Soft Tissue Sarcoma That Is Locally Advanced or Inoperable

Medical oncologist William Tap discusses a multicenter randomized study that compares doxorubicin plus TH-302 versus doxorubicin alone for locally advanced soft tissue sarcoma that is inoperable or metastatic.

Published: 09/04/2012 - 12:36 PM